Synopsis of recent research by authors named "Shuanglian Li"
- Shuanglian Li's recent research focuses on the regulatory roles of long non-coding RNAs and pharmacokinetics in various diseases, highlighting the impact of ANRIL on retinoblastoma and the pharmacokinetic properties of recombinant factors in hemophilia treatment.
- Findings indicate that the overexpression of ANRIL can inhibit miR-328-3p and promote autophagy in retinoblastoma cells, whilst maternal antibodies can exacerbate RSV-related lung inflammation in offspring, suggesting complex interactions between innate immunity and viral infections.
- Additionally, Li's work on phase II trials for novel lung cancer treatments demonstrates efforts to overcome resistance mutations and enhance efficacy, aligning with a broader goal of identifying new therapeutic pathways in oncology and other chronic conditions.*
